Changes in bacterial enzymes and PCR profiles of fecal bacteria from a patient with ulcerative colitis before and after antimicrobial treatments

Digestive Diseases and Sciences

Volumn 44, Issue 3, 1999, Pages 637-642

  Rafii, Fatemeh ^a,b   Ruseler van Embden, Johanneke G H ^a,b   Van Lieshout, L M C ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Antimicrobial agents; Enzymes; PCR; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; CEFADROXIL; CEFALEXIN; CEFTRIAXONE; CEFUROXIME AXETIL; CIPROFLOXACIN; FLUCONAZOLE; METRONIDAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; ENZYME ACTIVITY; ENZYME ANALYSIS; FECES MICROFLORA; HUMAN; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0033020768     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026634229934     Document Type: Article

References (28)

1. 1. Sartor RB: Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 92:5S-11S, 1997
2. 2. Jewell DP: Immunology of inflammatory bowel disease - an update. J Gastroenterol 30(suppl):78-82, 1995
3. 3. Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS: Environmental risk factors in inflammatory bowel disease. Hepato-Gastroenterol 43:381-393, 1996
4. 4. Benno P, Leijonmarck CE, Monsen U, Uribe A, Midvedt T: Functional alteration of the microflora in patients with ulcerative colitis. Scand J Gastroenterol 28:839-844, 1993
5. 5. Dieleman LA, Pena AS, Meuwissen SGM, Vaneer EP: Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Scand J Gastroenterol 32:99-104, 1997
6. 6. Keighley MR, Arabi Y, Dimock F, Burdon DW, Allan RN, Alexander-Williams J: Influence of inflammatory bowel disease in intestinal microflora. Gut 19:1099-1104, 1978
7. 7. Gaiffer MH, Holdsworth CD, Duerden BI: The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 35:238-243, 1991
8. 8. Gorbach SL, Nahas L, Plaut AG, Weinstein L, Patterson JF, Levitan R: Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis, relationship to severity of disease and chemotherapy. Gastroenterology 54:575-587, 1968
9. 9. Cooke EM: A quantitative comparison of the faecal flora of patients with ulcerative colitis and that of normal persons. J Pathol Bacteriol 9:439-444, 1967
10. 10. Chadwick VS, Anderson RP: The role of intestinal bacteria in etiology and maintenance of inflammatory bowel disease. In Human Colonic Bacteria: Role in Nutrition, Physiology and Pathology. GR Gibson and GT Macfarlane (ed). CRC Press, London, 1995
11. 11. Raouf AH, Tsai HH, Parker N, Hoffman J, Walker RJ, Rhodes JM: Sulphation of colonic and rectal mucin in inflammatory bowel disease: reduced sulphation of rectal mucus in ulcerative colitis. Clin Sci 83:623-626, 1992
12. 12. Tsai HH, Sunderland D, Gibson GR, Hart CA, Rhodes JM: A novel mucin sulfatase from human feces. Its identification, purification and characterization. Clin Sci 84:447-454, 1992
13. 13. Tsai HH, Dwarakanath AD, Hart CA, Milton JD, Rhodes JM: Increased mucin sulfatase activity in ulcerative colitis: a potential target for treatment. Gut 36:570-576, 1995
14. 14. Rowland IR: Toxicology of the colon: Role of intestinal microflora. In Human Colonic Bacteria: Role in Nutrition, Physiology and Pathology. GR Gibson and GT Macfarlane (ed). CRC Press, London, 1995
15. 15. Carrette O, Favier C, Mizon C, Neut C, Cortot A: Bacteria used for colon specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci 40:2641-2646, 1995
16. 16. Rafii F, Ruseler-Van Embden JGH, Asad YF: Azoreductase and nitroreductase activity of bacteria in feces from patients with an ileal reservoir. Dig Dis Sci 42:133-136, 1997
17. 17. Hoffman PS, Goodwin A, Johnsen J, Magee K, Veldhuyzen van Zanten SJO: Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: Repression of pyruvate oxidoreductase and expression resistance. J Bacteriol 178:4822-4829, 1996
18. 18. Ruseler-van Embden JG, van Lieshout LM: Increased fecal glycosidases in patients with Crohn's disease. Digestion 37:43-50, 1987
19. 19. Ruseler-van Embden JGH, Schouten WR, van Lieshout LMC: Pouchitis: Results of microbial imbalance? Gut 35:658-664, 1994
20. 20. Sambrook J, Fritsch FF, Maniatis T: Molecular Cloning: A Laboratory Manual, 2nd ed., Vol 3. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989, pp E3-E10
21. 21. Dumonceau JM, Adler M, Cremer M, Van Gossum A: The role of infectious agents in Crohn's disease. Acta Gastroenterol Belg 57:301-305, 1994
22. 22. Van Kruiningen HJ: On the use of antibiotics in Crohn's disease. J Clin Gastroenterol 20:310-316, 1995
23. 23. Hudson MJ, Hill MJ, Elliott PR, Berghouse LM, Burnham WR, Lennard-Jones JE: The microbial flora of the rectal mucosa and faeces of patients with Crohn's disease before and during antimicrobial chemotherapy. J Med Microbiol 18:335-345, 1984
24. 24. Fabia R, Ar'Rajab A, Johansson ML, Andersson R, Willen R, Jeppsson B, Molin G, Bengmark S: Impairment of bacterial flora in human ulcerative colitis and experimental colitis. Digestion 54:248-255, 1993
25. 25. Rhodes JM, Gallimore R, Elias E, Allan RN, Kennedy JF: Fecal mucus degrading glycosidase in ulcerative colitis and Crohn's disease. Gut 26:761-765, 1985
26. 26. Roediger WE, Duncan A, Kapaniris O, Millard S: Reducing sulfur compounds of the colon impair colonocyte nutrition: Implication for ulcerative colitis. Gastroenterology 104:802-809, 1993
27. 14C threonine labeled mucin substrate. Gut 37:58-62, 1995
28. 28. Schorr-Lesnick B, Brandt LJ: Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease. Am J Gastroenterol 82:216-233, 1988